These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 23511926)

  • 1. Ascites metabolism measurement enhanced the diagnostic value and accuracy of prognostic evaluation in 18F-FDG PET/CT studies in malignant ascites patients.
    Li XJ; Li FQ; Han JK; Zhao ZH; Song ZG; Dai XZ
    Nucl Med Commun; 2013 Jun; 34(6):544-50. PubMed ID: 23511926
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Role of 18F-FDG PET/CT in the evaluation of Ascites of Undetermined Origin.
    Zhang M; Jiang X; Zhang M; Xu H; Zhai G; Li B
    J Nucl Med; 2009 Apr; 50(4):506-12. PubMed ID: 19289438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Value of
    Han N; Sun X; Qin C; Hassan Bakari K; Wu Z; Zhang Y; Lan X
    AJR Am J Roentgenol; 2018 May; 210(5):1155-1163. PubMed ID: 29629798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the diagnostic and prognostic values of 99mTc-MDP-planar bone scintigraphy, 131I-SPECT/CT and 18F-FDG-PET/CT for the detection of bone metastases from differentiated thyroid cancer.
    Qiu ZL; Xue YL; Song HJ; Luo QY
    Nucl Med Commun; 2012 Dec; 33(12):1232-42. PubMed ID: 23111353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 18F-FDG PET/CT qualitative and quantitative evaluation in neurofibromatosis type 1 patients for detection of malignant transformation: comparison of early to delayed imaging with and without liver activity normalization.
    Chirindel A; Chaudhry M; Blakeley JO; Wahl R
    J Nucl Med; 2015 Mar; 56(3):379-85. PubMed ID: 25655626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic accuracy of (18)F-FDG PET/CT compared with that of contrast-enhanced MRI of the breast at 3 T.
    Magometschnigg HF; Baltzer PA; Fueger B; Helbich TH; Karanikas G; Dubsky P; Rudas M; Weber M; Pinker K
    Eur J Nucl Med Mol Imaging; 2015 Oct; 42(11):1656-1665. PubMed ID: 26121928
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in the characterization of pancreatic masses: experience from tropics.
    Santhosh S; Mittal BR; Bhasin D; Srinivasan R; Rana S; Das A; Nada R; Bhattacharya A; Gupta R; Kapoor R
    J Gastroenterol Hepatol; 2013 Feb; 28(2):255-61. PubMed ID: 23278193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of soft-tissue lesions with (18)F-FDG PET/CT: initial results of a prospective trial.
    Leal AL; Etchebehere M; Santos AO; Kalaf G; Pacheco EB; Amstalden EM; Etchebehere EC
    Nucl Med Commun; 2014 Mar; 35(3):252-9. PubMed ID: 24300379
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic accuracy of lymph node metastasis depends on metabolic activity of the primary lesion in thoracic squamous esophageal cancer.
    Manabe O; Hattori N; Hirata K; Itoh K; Hosokawa M; Takahashi H; Oyama-Manabe N; Tamaki N
    J Nucl Med; 2013 May; 54(5):670-6. PubMed ID: 23516310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Value of dual-time-point (18)F-fluorodeoxyglucose integrated positron emission and computed tomography in differentiation of malignant from benign gastrointestinal diseases].
    Xu XX; Cheng J; Xu WG; Dai D; Song XY; Ma WC; Zhu L; Zhu X
    Zhonghua Zhong Liu Za Zhi; 2012 May; 34(5):364-8. PubMed ID: 22883458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of fluorodeoxyglucose-positron emission tomography/computed tomography in differentiating between benign and malignant adrenal lesions.
    Ozcan Kara P; Kara T; Kara Gedik G; Kara F; Sahin O; Ceylan Gunay E; Sari O
    Nucl Med Commun; 2011 Feb; 32(2):106-12. PubMed ID: 21085046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The clinical efficacy of (18)F-FDG-PET/CT in benign and malignant musculoskeletal tumors.
    Shin DS; Shon OJ; Han DS; Choi JH; Chun KA; Cho IH
    Ann Nucl Med; 2008 Aug; 22(7):603-9. PubMed ID: 18756363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ¹¹C-methionine and ¹⁸F-fluorodeoxyglucose positron emission tomography/CT in the evaluation of patients with suspected primary and residual/recurrent gliomas.
    Li DL; Xu YK; Wang QS; Wu HB; Li HS
    Chin Med J (Engl); 2012 Jan; 125(1):91-6. PubMed ID: 22340472
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does hyperglycemia affect the diagnostic value of 18F-FDG PET/CT?
    Mirpour S; Meteesatien P; Khandani AH
    Rev Esp Med Nucl Imagen Mol; 2012; 31(2):71-7. PubMed ID: 22088805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In newly diagnosed diffuse large B-cell lymphoma, determination of bone marrow involvement with 18F-FDG PET/CT provides better diagnostic performance and prognostic stratification than does biopsy.
    Berthet L; Cochet A; Kanoun S; Berriolo-Riedinger A; Humbert O; Toubeau M; Dygai-Cochet I; Legouge C; Casasnovas O; Brunotte F
    J Nucl Med; 2013 Aug; 54(8):1244-50. PubMed ID: 23674577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The predictive value of C-reactive protein and erythrocyte sedimentation rate for 18F-FDG PET/CT outcome in patients with fever and inflammation of unknown origin.
    Balink H; Veeger NJ; Bennink RJ; Slart RH; Holleman F; van Eck-Smit BL; Verberne HJ
    Nucl Med Commun; 2015 Jun; 36(6):604-9. PubMed ID: 25738560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of FDG-PET/CT in evaluating surgical outcomes of operable breast cancer--usefulness for malignant grade of triple-negative breast cancer.
    Ohara M; Shigematsu H; Tsutani Y; Emi A; Masumoto N; Ozaki S; Kadoya T; Okada M
    Breast; 2013 Oct; 22(5):958-63. PubMed ID: 23756383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adrenal masses: the value of additional fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) in differentiating between benign and malignant lesions.
    Okada M; Shimono T; Komeya Y; Ando R; Kagawa Y; Katsube T; Kuwabara M; Yagyu Y; Kumano S; Imaoka I; Tsuchiya N; Ashikaga R; Hosono M; Murakami T
    Ann Nucl Med; 2009 Jun; 23(4):349-54. PubMed ID: 19340526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic value of metabolic tumor volume assessed by 18F-FDG PET/CT added to SUVmax for characterization of thyroid 18F-FDG incidentaloma.
    Kim BH; Kim SJ; Kim H; Jeon YK; Kim SS; Kim IJ; Kim YK
    Nucl Med Commun; 2013 Sep; 34(9):868-76. PubMed ID: 23797273
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic tumor volume assessed by 18F-FDG PET/CT for the prediction of outcome in patients with multiple myeloma.
    Fonti R; Larobina M; Del Vecchio S; De Luca S; Fabbricini R; Catalano L; Pane F; Salvatore M; Pace L
    J Nucl Med; 2012 Dec; 53(12):1829-35. PubMed ID: 23071351
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.